CNMD

CNMD is a mid-cap surgical-device company with a defensible mix — ~86% of revenue from single-use products and a roughly even orthopedics/general-surgery split — that grew the top line 5.2% to $1.37B in FY25. The franchise quality shows in a 54.6% gross margin and $171M of operating cash flow (+2.2% YoY), and the balance sheet has improved at the margin: equity up 7.3% to $1.03B, cash up 66.9% to $40.8M, and total liabilities down 3.8%. At $35.86 the stock trades at 0.8x sales and ~6.5x operating cash flow, which is undemanding for a medical-device platform.

The problem is what sits underneath the headline growth. Operating income fell 48.8% to $103M and net income collapsed 64.5% to $47.1M, dragging operating margin to 7.5% and ROE to a thin 4.6%. MD&A names the culprits directly — 'higher manufacturing and operating costs', 'ongoing supply chain challenges' and 'tariffs placed on imported goods' — serious enough that management 'engaged a consulting firm in 2025 to evaluate and propose improvements in our manufacturing operations'. They also ran a portfolio review that killed planned product lines and, on Dec 5 2025, announced the exit of the entire gastroenterology portfolio (terminating the Gore VIABIL distribution agreement effective Jan 1 2026). That is a tacit admission parts of the General Surgery segment (58% of sales) weren't earning their keep, and it brings near-term revenue dis-synergies even if it improves mix.